Eidos Therapeutics Inc. 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-01-26 4:23 pm Sale | 2021-01-26 | 13D | BridgeBio Pharma, Inc. BBIO | Eidos Therapeutics Inc. EIDX | 0 0.000% | -44,651,896 (Position Closed) | Filing |